Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31403818)

  • 1. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
    Griffith SD; Miksad RA; Calkins G; You P; Lipitz NG; Bourla AB; Williams E; George DJ; Schrag D; Khozin S; Capra WB; Taylor MD; Abernethy AP
    JCO Clin Cancer Inform; 2019 Aug; 3():1-13. PubMed ID: 31403818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
    Griffith SD; Tucker M; Bowser B; Calkins G; Chang CJ; Guardino E; Khozin S; Kraut J; You P; Schrag D; Miksad RA
    Adv Ther; 2019 Aug; 36(8):2122-2136. PubMed ID: 31140124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
    Torres AZ; Nussbaum NC; Parrinello CM; Bourla AB; Bowser BE; Wagner S; Tabano DC; George D; Miksad RA
    Adv Ther; 2022 Jun; 39(6):2831-2849. PubMed ID: 35430670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    Stewart M; Norden AD; Dreyer N; Henk HJ; Abernethy AP; Chrischilles E; Kushi L; Mansfield AS; Khozin S; Sharon E; Arunajadai S; Carnahan R; Christian JB; Miksad RA; Sakoda LC; Torres AZ; Valice E; Allen J
    JCO Clin Cancer Inform; 2019 Jul; 3():1-15. PubMed ID: 31335166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
    Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
    Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    Li Y; Appius A; Pattipaka T; Feyereislova A; Cassidy A; Ganti AK
    PLoS One; 2019; 14(1):e0209709. PubMed ID: 30608948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
    Davies J; Martinec M; Coudert M; Delmar P; Crane G
    Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
    Siah KW; Khozin S; Wong CH; Lo AW
    JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
    Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
    Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes in patients with unresected stage III non-small cell lung cancer.
    Ryan KJ; Skinner KE; Fernandes AW; Punekar RS; Pavilack M; Walker MS; VanderWalde NA
    Med Oncol; 2019 Jan; 36(3):24. PubMed ID: 30706218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
    Ma X; Bellomo L; Magee K; Bennette CS; Tymejczyk O; Samant M; Tucker M; Nussbaum N; Bowser BE; Kraut JS; Bourla AB
    Adv Ther; 2021 Apr; 38(4):1843-1859. PubMed ID: 33674928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.